ND0612H: Phase IIa started

NeuroDerm began the observer-blind, international Phase IIa ND0612H-006 trial to compare 2 dosing regimens of continuous subcutaneous infusion of ND0612H over 14 or 24 hours vs. the baseline oral stan...